Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2006, for AVI BioPharma, Inc. (Note: The input metadata referenced "Sarepta Therapeutics," but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is a development-stage biopharmaceutical firm focused on antisense therapeutics. It has not generated material revenue from product sales and expects to incur operating losses for the foreseeable future.
Key Financial Metrics
| Metric | Q3 2006 | Q3 2005 | 9 Months 2006 | 9 Months 2005 |
|---|---|---|---|---|
| Revenues | $13,252 | $3,281,805 | $97,772 | $3,366,314 |
| Net Loss | $(6,780,646) | $(1,692,471) | $(22,743,825) | $(12,124,292) |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.04) | $(0.43) | $(0.28) |
| Cash & Equivalents (End of Period) | $25,578,248 | $27,556,780 | $25,578,248 | $27,556,780 |
| Total Assets | $46,542,091 | $56,407,982 | $46,542,091 | $56,407,982 |
| Accumulated Deficit | $(195,392,069) | $(172,648,244) | $(195,392,069) | $(172,648,244) |
Liquidity: As of September 30, 2006, the company held approximately $38.4 million in cash, cash equivalents, and short-term securities. Management believes this is sufficient to fund operations through 2007.
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped significantly in Q3 2006 ($13k) compared to Q3 2005 ($3.28M). The 2005 figure included a one-time recognition of $3.22M in research contract revenue from government funding for viral disease research, which did not recur in 2006.
- Increased Operating Expenses: Total operating expenses rose to $7.29M in Q3 2006 from $5.20M in Q3 2005.
- R&D: Increased by ~$1.79M, driven by higher employee costs (including $645k in stock-based compensation under new SFAS 123R rules), expanded clinical programs (hepatitis C and coronary artery bypass grafting), and GMP production costs.
- G&A: Increased by ~$295k, primarily due to higher employee costs and stock-based compensation, partially offset by the departure of nine employees to Cook Group Inc.
- Stock-Based Compensation: The adoption of SFAS 123R on January 1, 2006, increased net loss by approximately $1.0M for the quarter and $3.1M for the nine-month period.
Guidance, Outlook, and Risks
- Outlook: The company expects to incur losses for the foreseeable future. It anticipates 2006 operating expenditures (including collaborative efforts and GMP facilities) to be between $23 million and $25 million.
- Strategic Agreements:
- Cook Group Inc.: Entered into agreements for the development of vascular/cardiovascular products. AVI sold 692,003 shares to Cook for net proceeds of $4.96M.
- Chiron Corporation: Secured a non-exclusive license for hepatitis C therapeutics. AVI issued 89,012 shares (valued at $500k) as the first milestone payment.
- Government Funding: The 2006 defense appropriations act allocated $11 million for AVI's defense-related programs (Ebola, Marburg, dengue, anthrax, ricin). This funding has not yet been received and is not reflected in the financial statements.
- Risks: The company faces significant risks regarding the ability to raise additional capital beyond 2007, the success of clinical trials, regulatory approvals, and the commercialization of products. There is no assurance of future profitability.
Investor Verification Checklist
- Company Identity: Verify that the filing is for AVI BioPharma, Inc., not Sarepta Therapeutics (metadata discrepancy).
- Cash Runway: Confirm the sufficiency of the $38.4M cash position to cover the projected $23M-$25M annual burn rate through 2007.
- Revenue Recurrence: Assess the likelihood of recurring revenue given the drop from $3.28M in Q3 2005 to $13k in Q3 2006.
- Government Grant Status: Monitor the receipt and utilization of the $11M defense appropriation announced in January 2006.
- Stock-Based Compensation: Review the impact of SFAS 123R on future earnings, as non-cash charges significantly inflated the reported net loss.